We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 26 for:    GLPG0634
Previous Study | Return to List | Next Study

Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02048618
First Posted: January 29, 2014
Last Update Posted: February 23, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Galapagos NV
  Purpose
  • 180 patients suffering from active Crohn's disease with evidence of mucosal ulceration will be evaluated for improvement of disease activity (efficacy) when taking GLPG0634 or matching placebo once daily for 20 weeks in addition to their stable background treatment.
  • During the course of the study, patients will also be examined for any side effects that may occur (safety and tolerability), and the amount of GLPG0634 present in the blood (Pharmacokinetics) as well as the effects of GLPG0634 on disease- and mechanism of action-related parameters in the blood and stool (Pharmacodynamics) will be determined. Also, the effects GLPG0634 administration on subjects' quality of life will be evaluated.

Condition Intervention Phase
Crohn's Disease Drug: GLPG0634 Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study to Investigate the Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease With Evidence of Mucosal Ulceration

Resource links provided by NLM:


Further study details as provided by Galapagos NV:

Primary Outcome Measures:
  • Percentage of subjects achieving clinical remission at Week 10 [ Time Frame: Week 10 ]
    Percentage of subjects achieving clinical remission as defined by a Crohn's Disease Activity Index score < 150 points


Secondary Outcome Measures:
  • Percentage of subjects achieving clinical remission [ Time Frame: Up to Week 20 ]
    Percentage of subjects achieving clinical remission as defined by a Crohn's Disease Activity Index score < 150 points, assessed at every visit

  • Percentage of subjects achieving clinical response [ Time Frame: Up to Week 20 ]
    Percentage of subjects achieving clinical response as defined by a decrease in Crohn's Disease Activity Index score of at least 100 points, assessed at every visit

  • Percentage of subjects achieving endoscopic remission at Week 10 [ Time Frame: Week 10 ]
    Percentage of subjects achieving endoscopic remission as defined by a reduction of Simplified Endoscopy Score for Crohn's Disease (SES-CD) score ≤ 4, with ulcerated surface subscore no greater than 1 in any segment at Week 10

  • Percentage of subjects achieving endoscopic response at Week 10 [ Time Frame: Week 10 ]
    Percentage of subjects achieving endoscopic response as defined by a reduction of Simplified Endoscopy Score for Crohn's Disease (SES-CD) score by at least 50% from Screening at Week 10

  • Percentage of subjects achieving mucosal healing at Week 10 [ Time Frame: Week 10 ]
    Percentage of subjects achieving mucosal healing as defined by a Simplified Endoscopy Score for Crohn's Disease (SES-CD) score equal to 0 at Week 10

  • Change from Baseline in Crohn's Disease Activity Index score [ Time Frame: Up to Week 20 ]
    Change from Baseline in Crohn's Disease Activity Index score, assessed at every visit

  • Change from Screening in endoscopic score [ Time Frame: Week 10 ]
    Change from Screening in endoscopic Simplified Endoscopy Score for Crohn's Disease (SES-CD) score at Week 10

  • Change from Screening in histopathology biopsy score [ Time Frame: Week 10 ]
    Change from Screening in histopathology biopsy score at Week 10

  • Change from Baseline in Subjects' Quality of Life (based on the Inflammatory Bowel Disease Questionnaire (IBDQ) questionnaire score) [ Time Frame: Up to Week 20 ]
    Change from Baseline in Subjects' Quality of Life based on the IBDQ questionnaire score at Week 10 and Week 20

  • The number of subjects with adverse events [ Time Frame: From screening up to 2 weeks after last dose ]
    To evaluate the safety and tolerability of GLPG0634 in comparison with placebo in terms of adverse events (AEs)

  • The number of subjects with abnormal lab tests [ Time Frame: From screening up to 2 weeks after last dose ]
    To evaluate the safety and tolerability of GLPG0634 in comparison with placebo in terms laboratory test abnormalities

  • The number of subjects with abnormal vital signs [ Time Frame: From screening up to 2 weeks after last dose ]
    To evaluate the safety and tolerability of GLPG0634 in comparison with placebo in terms of abnormalities in vital signs

  • The number of subjects with abnormal ECG [ Time Frame: From screening up to 2 weeks after last dose ]
    To evaluate the safety and tolerability of GLPG0634 in comparison with placebo in terms of abnormalities in electrocardiogram (ECG)

  • The plasma levels of GLPG0634 and its metabolite [ Time Frame: Up to Week 20 ]
    To characterize the pharmacokinetics (PK) of GLPG0634 and its metabolite by measuring the amount in plasma from Week 2 up to Week 20 at every visit

  • The change versus Baseline in levels of immune- and inflammation-related parameters in whole blood and serum [ Time Frame: Up to Week 20 ]
    To characterize the pharmacodynamics (PD) of GLPG0634 and its metabolite by measuring the levels of immune- and inflammation-related parameters in whole blood and serum

  • The change versus Baseline in levels of faecal calprotectin [ Time Frame: Up to Week 20 ]
    To characterize the pharmacodynamics (PD) of GLPG0634 and its metabolite by measuring the levels of faecal calprotectin

  • The change versus Baseline in microbial communities in stool samples [ Time Frame: Up to Week 10 ]
    To characterize the effects of GLPG0634 and its metabolite on the microbial communities by measuring the levels of predominant microbiota in stool samples


Enrollment: 175
Study Start Date: February 2014
Study Completion Date: February 2016
Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GLPG0634 200 mg QD
2 tablets of 100 mg GLPG0634 in the morning
Drug: GLPG0634
100 mg oral tablet, intake once daily for 20 weeks
Other Name: GLPG0634 tablets
Experimental: GLPG0634 100 mg QD
1 tablet of 100 mg GLPG0634 and 1 placebo tablet in the morning
Drug: GLPG0634
100 mg oral tablet, intake once daily for 20 weeks
Other Name: GLPG0634 tablets
Drug: Placebo
placebo oral tablets, intake once daily for 20 weeks
Other Name: Placebo tablets
Placebo Comparator: Placebo QD
2 placebo tablets in the morning
Drug: Placebo
placebo oral tablets, intake once daily for 20 weeks
Other Name: Placebo tablets

Detailed Description:
  • 180 patients suffering from active Crohn's disease with evidence of mucosal ulceration will be evaluated when taking GLPG0634 or matching placebo once daily in addition to their stable background treatment. The population will include 50% anti-TNF naïve patients and 50% of subjects previously exposed to anti-TNF.
  • The study will consist of 2 parts, with total treatment duration of 20 weeks. Randomisation in Part 1 will be stratified according to subject's previous anti-TNF exposure, C-reactive protein (CRP) level at Screening and oral corticosteroid use at Day -1. However, at Week 10, subjects will be re-randomized automatically and stratified according to the subject's clinical response (reduction of Crohn's Disease Activity Index (CDAI) of 100 points), previous anti-TNF exposure and corticosteroid use at Day -1 to receive GLPG0634 200 mg q.d., 100 mg q.d. doses, or matching placebo q.d. in a blinded fashion. In Part 2, all will continue the study until Week 20.
  • As efficacy parameters, the ability to achieve clinical response or remission, endoscopic response & remission as well as mucosal healing with GLPG0634 given once daily compared to placebo will be evaluated after 10 weeks of treatment. In subjects who achieved clinical remission at Week 10, maintenance of the remission will be assessed during Part 2 of the study.
  • During the course of the study, patients will also be examined for any side effects that may occur (safety and tolerability), and the amount of GLPG0634 present in the blood (Pharmacokinetics) as well as the effects of GLPG0634 on disease- and mechanism of action-related parameters in the blood and stool (Pharmacodynamics) will be determined. Also, the effects of different doses and dose regimens of GLPG0634 administration on subjects' quality of life will be evaluated.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subjects between 18 and 75 years
  • Documented history of ileal, colonic, or ileocolonic CD
  • CDAI score ≥ 220 to ≤ 450
  • Evidence of active inflammation as demonstrated by endoscopic confirmation of active disease
  • Subjects previously not exposed to anti-TNF treatment (TNF-naïve) or subjects previously exposed to anti-TNF therapy at a registered dose, that has been discontinued at least 8 weeks prior to Screening and deemed by the treating physician as a primary or secondary non-responder or intolerant (TNF-experienced)
  • Continuation of concurrent treatment with oral steroids (≤30 mg prednisolone eq/day), mesalazine, olsalazine, CD-related antibiotics and probiotics at stable dose is allowed
  • Previous exposure to immunomodulators is permitted, but must be discontinued
  • Haematology and biochemistry lab parameters within predefined ranges as stated in the protocol

Exclusion Criteria:

  • Diagnosis of indeterminate colitis, ulcerative colitis (UC), or clinical findings suggestive of UC
  • Stoma, gastric or ileoanal pouch, procto- or total colectomy, symptomatic stenosis or obstructive strictures, history of bowel perforation, (suspected) abscess; actively draining fistulae
  • Subject who has had surgical bowel resections within the past 6 months, short bowel syndrome or is receiving tube feeding, defined formula diets, or parenteral alimentation
  • Subject with positive Clostridium difficile toxin stool assay or evidence of any other gastrointestinal infection
  • Subject who has received non-permitted IBD therapies within specified timeframes, depending on the medication, as stated in the protocol
  • Subject with a (previous history of) dysplasia of the gastrointestinal tract
  • Concurrent gastro-intestinal malignancy or a history of cancer elsewhere
  • History of lymphoproliferative disease
  • Known active infection of any kind, current therapy for chronic infection or history of specific infections as stated in the protocol
  • Subject who is pregnant, lactating or not willing to maintain highly effective birth control methods during the course of the study and 12 weeks thereafter
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02048618


  Show 63 Study Locations
Sponsors and Collaborators
Galapagos NV
Investigators
Study Director: Pille Harrison, MD Galapagos NV
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Galapagos NV
ClinicalTrials.gov Identifier: NCT02048618     History of Changes
Other Study ID Numbers: GLPG0634-CL-211
2013-002857-32 ( EudraCT Number )
First Submitted: January 27, 2014
First Posted: January 29, 2014
Last Update Posted: February 23, 2016
Last Verified: February 2016

Keywords provided by Galapagos NV:
Active Crohn's Disease
GLPG0634

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases